BlossomHill Therapeutics (NASDAQ:BLSM) Reaches New 12-Month High – What’s Next?

BlossomHill Therapeutics, Inc. (NASDAQ:BLSMGet Free Report) reached a new 52-week high on Tuesday . The company traded as high as $17.54 and last traded at $17.22, with a volume of 69520 shares trading hands. The stock had previously closed at $16.03.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen raised BlossomHill Therapeutics to a “hold” rating in a report on Saturday, August 15th.

View Our Latest Research Report on BLSM

BlossomHill Therapeutics Stock Performance

Insider Activity

In other news, Director Carl L. Gordon acquired 625,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was bought at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the completion of the acquisition, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This represents a 29.91% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Orbimed Advisors Llc acquired 625,000 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was purchased at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the transaction, the director owned 2,714,279 shares of the company’s stock, valued at approximately $43,428,464. This trade represents a 29.91% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought a total of 1,573,900 shares of company stock valued at $25,181,900 in the last three months.

BlossomHill Therapeutics Company Profile

(Get Free Report)

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.

Recommended Stories

Receive News & Ratings for BlossomHill Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BlossomHill Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.